1
|
Salinero LK, Friedman L, Shulkin JM, Barrero CE, Wagner CS, Pontell ME, Swanson JW, Bartlett SP, Nah HD, Taylor JA. Orthognathic Considerations of Maxillary and Mandibular Asymmetry at Skeletal Maturity in Patients with Cleft Lip and Palate. Plast Reconstr Surg 2024:00006534-990000000-02305. [PMID: 38589997 DOI: 10.1097/prs.0000000000011463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2024]
Abstract
BACKGROUND Improving occlusion and aesthetics is the primary objective of orthognathic surgery for patients with cleft lip and palate (CLP). However, these patients often suffer from horizontal, vertical, and rotational asymmetry in addition to maxillary retrusion. This study aims to describe maxillary and mandibular asymmetry in patients with CLP undergoing orthognathic surgery and analyze its anatomic basis. METHODS Patients with isolated CLP undergoing CT imaging prior to orthognathic surgery were retrospectively reviewed. Maxillary and mandibular positioning and dimensional symmetry were evaluated. Incidence of clinically significant asymmetry, correlations between areas of asymmetry, and associations with clinical history were analyzed. RESULTS Fifty-eight patients, with mean age 17 years were analyzed, including 32 patients with unilateral CLP and 26 with bilateral CLP. Twenty (34%) patients demonstrated chin deviation ≥4mm and 21 (36%) had a ≥5% discrepancy in mandibular ramus lengths. Horizontal occlusal plane cant of ≥2° was seen in 20 (34%) maxillae and 28 (48%) mandibles, with dental arch yaw ≥2° noted in 32 (55%) of both maxillae and mandibles. Chin deviation correlated with maxillary cant, discrepancy in ramus length, discrepancy in mandibular body length, and discrepancy in condylar volume (p<0.05). Bilateral and unilateral CLP did not show significantly different asymmetry on any measure (p>0.05). CONCLUSIONS Both maxillary and mandibular asymmetry is common in skeletally mature patients with CLP and frequently results in notable chin deviation. Preoperative three-dimensional imaging and virtual surgical planning of orthognathic surgery aid in recognition of facial asymmetries and reveal opportunities to optimize results in this population.
Collapse
Affiliation(s)
- Lauren K Salinero
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Romeo DJ, Oral KT, Ng JJ, Wu M, Massenburg BB, Salinero LK, Friedman L, Bartlett SP, Swanson JW, Taylor JA. Mandibular condyle volumes are associated with facial asymmetry in patients with cleft lip and palate: A retrospective cohort study. J Craniomaxillofac Surg 2024; 52:472-476. [PMID: 38378367 DOI: 10.1016/j.jcms.2024.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 12/24/2023] [Accepted: 01/16/2024] [Indexed: 02/22/2024] Open
Abstract
This study compares condylar volumetric asymmetry and facial asymmetry in patients with cleft lip and/or palate (CLP) and controls. The mandibular condyle is important to facial growth, but its role in facial asymmetry for those with CLP has not been described. Condylar volumes and mandibular asymmetry were retrospectively calculated using Mimics Version 23.0 (Materialise, Leuven, Belgium) from patients with CLP undergoing computed tomography (CT) imaging and a cohort of controls. A total of 101 participants, 60 with CLP and 41 controls, had mean condylar volumetric asymmetry of 16.4 ± 17.4 % (CLP) and 6.0 ± 4.0 % (controls) (p = 0.0002). Patients with CLP who had clinically significant chin deviation (>4 mm) had more asymmetric condyles than those without significant chin deviation (p = 0.003). The chin deviated toward the smaller condyle in patients with facial asymmetry more often than in patients without facial asymmetry (81 % vs. 62 %, p = 0.033). While controls had some degree of condylar asymmetry, it tended to be milder and not associated with facial asymmetry. There is a greater degree of condylar volumetric asymmetry in patients with CLP compared to individuals in the general population. Clinically significant facial asymmetry in CLP is associated with a higher degree of condylar asymmetry, with the facial midline deviating toward the smaller condyle.
Collapse
Affiliation(s)
- Dominic J Romeo
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Kaan T Oral
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Jinggang J Ng
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Meagan Wu
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Benjamin B Massenburg
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Lauren K Salinero
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Leigh Friedman
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Scott P Bartlett
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Jordan W Swanson
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA
| | - Jesse A Taylor
- Division of Plastic, Reconstructive and Oral Surgery, Children's Hospital of Philadelphia, USA.
| |
Collapse
|
3
|
Salinero LK, Romeo DJ, Pontell ME, Friedman L, Ahluwalia VS, Wagner CS, Barrero CE, Napoli J, Jackson OA, Low DW, Bartlett SP, Swanson J, Magee L, Taylor JA. Psychosocial Status and Self-Perception in Patients with Cleft Lip and/or Palate. Cleft Palate Craniofac J 2024:10556656241236369. [PMID: 38436069 DOI: 10.1177/10556656241236369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/05/2024] Open
Abstract
OBJECTIVE To describe how the psychosocial status of patients with cleft lip and/or palate (CL/P) relates to patient-reported outcomes (PROs). DESIGN Cross-sectional retrospective chart review. SETTING Tertiary care pediatric hospital. PATIENTS/PARTICIPANTS Patients aged 8 to 29 years attending cleft team evaluations during a 1-year period. MAIN OUTCOME MEASURES CLEFT-Q. RESULTS Patients (N = 158) with isolated or syndromic CL/P and mean age 13.4 ± 3.0 years were included. Fifteen (9%) patients had siblings who also had CL/P. Of 104 patients who met with the team psychologist, psychosocial concerns were identified in 49 (47%) patients, including 25 (24%) with Attention-Deficit/Hyperactivity Disorder or behavior concerns, 28 (27%) with anxiety, and 14 (13%) with depression or mood concerns. Younger age and having siblings with cleft were associated with better PROs, while psychosocial concerns were associated with worse PROs on Speech, Psychosocial, and Face Appearance scales. CONCLUSIONS Patient perception of cleft outcomes is linked to psychosocial factors.
Collapse
Affiliation(s)
- Lauren K Salinero
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Dominic J Romeo
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Matthew E Pontell
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Leigh Friedman
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Vinayak S Ahluwalia
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Connor S Wagner
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Carlos E Barrero
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Joseph Napoli
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Oksana A Jackson
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - David W Low
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Scott P Bartlett
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Jordan Swanson
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Leanne Magee
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Jesse A Taylor
- Division of Plastic, Reconstructive, and Oral Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| |
Collapse
|
4
|
Knoedler S, Knoedler L, Hoch CC, Kauke-Navarro M, Kehrer A, Friedman L, Prantl L, Machens HG, Orgill DP, Panayi AC. An ACS-NSQIP Data Analysis of 30-Day Outcomes Following Surgery for Bell's Palsy. J Craniofac Surg 2024; 35:23-28. [PMID: 37695075 PMCID: PMC10841222 DOI: 10.1097/scs.0000000000009739] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 07/31/2023] [Indexed: 09/12/2023] Open
Abstract
BACKGROUND There exists a paucity of large-scale, multi-institutional studies that investigate the outcomes of surgery for Bell's palsy (BP). Here, we utilize a large, multi-institutional database to study the risk factors and early-stage outcomes following surgical procedures in BP. METHODS We reviewed the American College of Surgeons National Surgical Quality Improvement Program database (2008-2019) to identify patients who underwent surgery for the diagnosis of BP. We extracted data on comorbidities and preoperative blood values, and 30-day postoperative outcomes. RESULTS Two hundred fifty-seven patients who underwent surgery for BP symptoms over the 12-year review period were identified. Muscle grafts (n=50; 19%) and fascial grafts (n=48; 19%) accounted for the majority of procedures. The most common comorbidities were hypertension (n=89; 35%) and obesity (n=79; 31%). Complications occurred in 26 (10.1%) cases. Additionally, length of hospital stay was significantly associated with both surgical and medical complications (3.9±4.7 versus 1.5±2.0; P <0.01) and (3.2±3.8 versus 1.4±2.0; P <0.01), respectively. Preoperative creatinine, blood urea nitrogen, and alkaline phosphatase were identified as potential predictors of poor postoperative outcomes. CONCLUSION Based on multi-institutional analysis, complication rates following surgery for BP were found to be overall low and seen to correlate with length of hospital stay. Reoperations and readmissions were the most frequent complications after surgery for BP. The preoperative evaluation of routine laboratory values may help refine patient eligibility and risk stratification. In addition, our findings call for future large-scale prospective studies in the field of facial palsy surgery to further improve the quality of care and optimize perioperative protocols.
Collapse
Affiliation(s)
- Samuel Knoedler
- Division of Plastic Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Department of Plastic and Hand Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - Leonard Knoedler
- Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
| | - Cosima C. Hoch
- Department of Otolaryngology, Head and Neck Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - Martin Kauke-Navarro
- Department of Surgery, Division of Plastic Surgery, Yale School of Medicine, New Haven, CT, USA
| | - Andreas Kehrer
- Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
| | - Leigh Friedman
- Division of Plastic Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Lukas Prantl
- Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
| | - Hans-Guenther Machens
- Department of Plastic and Hand Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - Dennis P. Orgill
- Division of Plastic Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Adriana C. Panayi
- Division of Plastic Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
5
|
Patel H, Camacho JM, Salehi N, Garakani R, Friedman L, Reid CM. Journeying Through the Hurdles of Gender-Affirming Care Insurance: A Literature Analysis. Cureus 2023; 15:e36849. [PMID: 37123806 PMCID: PMC10142323 DOI: 10.7759/cureus.36849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 03/29/2023] [Indexed: 03/31/2023] Open
Abstract
Gender-affirming surgery (GAS) has been proven to be successful in the treatment of gender dysphoria. The benefits of providing insurance coverage for transition-related surgeries far surpass the costs of suffering from persistent gender dysphoria, including many positive health outcomes such as decreased rates of substance use, psychiatric illness, and suicide. Despite being deemed a medical necessity, discrepancies in access to treatment and insurance coverage for GAS persist. The purpose of this review is to understand the impact of limited insurance coverage on the well-being of transgender patients. A comprehensive search was conducted utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in SCOPUS and PubMed databases using the terms "insurance" AND "gender affirming surgery." Articles in non-English languages were excluded. Data related to variations in insurance coverage for GAS in the United States were collected. Of the 67 articles reviewed, 29 met the inclusion criteria. When compared to the general population, individuals who identify as transgender have higher rates of being uninsured as of 2020, with only 30 states in the United States providing insurance coverage for transgender and gender non-binary people. Of the 30 states, only 18 provide coverage for GAS, with chondrolaryngoplasty having the highest prevalence of coverage. As evidenced in our review, the persistence of complex insurance regulations impedes transgender individuals' access to equitable care. Overall, this literature review elucidates the variability in insurance coverage as it relates to gender-affirming care. Furthermore, this review highlights the need for additional health policy reforms, in addition to improving physician awareness regarding the hurdles of navigating the insurance world as a transgender patient.
Collapse
|
6
|
Wu M, Matar DY, Yu Z, Chen Z, Knoedler S, Ng B, Darwish O, Haug V, Friedman L, Orgill DP, Panayi AC. Modulation of Lymphangiogenesis in Incisional Murine Diabetic Wound Healing Using Negative Pressure Wound Therapy. Adv Wound Care (New Rochelle) 2023. [PMID: 36424821 DOI: 10.1089/wound.2022.0074] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Objective: Despite the significant function of lymphatics in wound healing, and frequent clinical use of Negative Pressure Wound Therapy (NPWT), the effect of mechanical force application on lymphangiogenesis remains to be elucidated. We utilize a murine incisional wound healing model to assess the mechanisms of lymphangiogenesis following NPWT. Approach: Dorsal incisional skin wounds were created on diabetic mice (genetically obese leptin receptor-deficient mice [db/db]; n = 30) and covered with an occlusive dressing (Control, n = 15) or NPWT (-125 mmHg, continuous, 24 h for 7 days; NPWT, n = 15). The wounds were macroscopically assessed for 28 days. Tissue was harvested on day 10 for analysis. Qualitative functional analysis of lymphatic drainage was performed on day 28 using Evans Blue staining (n = 2). Results: NPWT increased lymphatic vessel density (40 ± 20 vs. 12 ± 6 podoplanin [PDPN]+ and 25 ± 9 vs. 14 ± 8 lymphatic vessel endothelial receptor 1 [LYVE-1]+) and vessel diameter (28 ± 9 vs. 12 ± 2 μm). Western blotting verified the upregulation of LYVE-1 with NPWT. Leukocyte presence was higher with NPWT (22% ± 3.7% vs. 9.1% ± 4.1% lymphocyte common antigen [CD45]+) and the leukocytes were predominately B cells clustered within vessels (8.8% ± 2.5% vs. 18% ± 3.6% B-lymphocyte antigen CD20 [CD20]+). Macrophage presence was lower in the NPWT group. Lymphatic drainage was increased in the NPWT group, which exhibited greater Evans Blue positivity. Innovation: The lymphangiogenic effects take place independent of macrophage infiltration, appearing to correlate with B cell presence. Conclusion: NPWT promotes lymphangiogenesis in incisional wounds, significantly increasing the lymph vessel density and diameter. This study highlights the potential of NPWT to stimulate lymphatic drainage and wound healing of surgical incisions.
Collapse
Affiliation(s)
- Mengfan Wu
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Plastic Surgery, Peking University Shenzhen Hospital, Shenzhen, China
| | - Dany Y Matar
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA
| | - Zhen Yu
- Opthalmology Department, Shenzhen Eye Hospital, Shenzhen Key Ophthalmic Laboratory, Jinan University, Shenzhen, China.,Angiogenesis Laboratory, Ophthalmology Department, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, USA
| | - Ziyu Chen
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Samuel Knoedler
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department for Plastic Surgery and Hand Surgery, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
| | - Brian Ng
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA
| | - Oliver Darwish
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, California Northstate University College of Medicine, Elk Grove, California, USA
| | - Valentin Haug
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
| | - Leigh Friedman
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Lehigh University, Bethlehem, Pennsylvania, USA.,Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA
| | - Dennis P Orgill
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Adriana C Panayi
- Division of Plastic Surgery, Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,Department of Hand, Plastic and Reconstructive Surgery, Microsurgery, Burn Center, BG Trauma Center Ludwigshafen, University of Heidelberg, Ludwigshafen, Germany
| |
Collapse
|
7
|
Ozeri Galai E, Friedman L, Tilley S, Hill D, Faerman A, Hart G. 604 SpliSense's antisense oligonucleotide SPL84-23-1 properly distributes and is retained in cystic fibrosis-like mice lungs. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01294-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
8
|
Hart G, Galai EO, Friedman L, Tilley S, Jania C, Hill D, Faerman A. ePS6.07 SpliSense’s ASO SPL84-23-1 properly distributes and is retained in cystic fibrosis-like mice lungs. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)00333-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Ong C, Daemen A, Merrick K, O'Brien T, Friedman L, Hatzivassiliou G. Abstract P5-04-26: Identification of preclinical mechanisms driving acquired resistance to endocrine therapy in estrogen-receptor positive (ER+) breast cancer cells. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-04-26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogen Receptor positive (ER+) breast cancer accounts for the majority of breast cancer cases and standard of care for these tumors is treatment with endocrine therapy, including the blockade of estrogen production (i.e. aromatase inhibitors; AIs) as well as the use of antagonists of ER function, i.e. selective estrogen receptor modulators (SERMs, i.e. tamoxifen) and selective estrogen receptor degraders (SERDs, i.e. fulvestrant). Despite the initial dependency of ER+ breast tumors on estrogen and ER for their survival and proliferation, treatment in the metastatic setting invariably leads to therapeutic resistance. While mechanisms of resistance to AIs include mutations in the estrogen receptor gene ESR1, less is known about mechanisms of resistance to SERMs and SERDs, thus it is essential to further investigate the latter, in order to successfully treat relapsed patients. To pre-clinically model cell-autonomous acquired resistance to these agents, we used T47D, an ER+ and p53- estrogen-responsive cell line treated with increasing concentrations of the SERM/SERD hybrid (SSH) ER-targeting agent GDC-0810 over the period of several months during which individual clones with acquired resistance to GDC-0810 were selected. GDC-0810-resistant clones were cross-resistant to other endocrine agents, including SERMs (tamoxifen) and SERDs (fulvestrant), consistent with general loss of dependency on ER. Surprisingly, the cells also lost sensitivity to palbociclib, the latter likely linked to their loss of one copy of the retinoblastoma (Rb) tumor suppressor gene. Comprehensive genetic and phenotypic characterization of the resistant clones relative to the parental cells revealed multiple mutations and deletions in DNA repair and cell cycle genes, and associated defects in DNA repair and cell cycle checkpoints. Cell cycle, proteomic, and mRNA expression analysis of parental versus resistant clones at baseline and upon DNA damage, identified a distinct cell cycle profile in the GDC-0810-resistant clones, characterized by accumulation of cells in the mitotic phase. A broad chemical screen identified pharmacologic inhibitors of cell cycle regulators and chemotherapeutic drug classes that preferentially target the ER-independent, GDC-0810 resistant clones compared to the parental cells. Our work provides novel insights into mechanisms and biomarkers of acquired resistant to estrogen therapies in ER+ breast cancer and reveals the acquisition of actionable dependencies that may potentially be exploited in resistant tumors. Furthermore, our studies provide rationale for testing specific chemotherapy regimens upon endocrine resistance accompanied by cell cycle and DNA repair checkpoint dysfunction in ER+ breast cancer.
Citation Format: Ong C, Daemen A, Merrick K, O'Brien T, Friedman L, Hatzivassiliou G. Identification of preclinical mechanisms driving acquired resistance to endocrine therapy in estrogen-receptor positive (ER+) breast cancer cells [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-26.
Collapse
Affiliation(s)
- C Ong
- Genentech, Inc, South San Francisco, CA
| | - A Daemen
- Genentech, Inc, South San Francisco, CA
| | - K Merrick
- Genentech, Inc, South San Francisco, CA
| | - T O'Brien
- Genentech, Inc, South San Francisco, CA
| | | | | |
Collapse
|
10
|
Mouton A, Blanc F, Gros A, Manera V, Fabre R, Sauleau E, Gomez-Luporsi I, Tifratene K, Friedman L, Thümmler S, Pradier C, Robert PH, David R. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study. Alzheimers Res Ther 2018; 10:92. [PMID: 30208961 PMCID: PMC6136211 DOI: 10.1186/s13195-018-0417-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 07/31/2018] [Indexed: 01/09/2023]
Abstract
Background Gender distribution varies across neurodegenerative disorders, with, traditionally, a higher female frequency reported in Alzheimer’s disease (AD) and a higher male frequency in Parkinson’s disease (PD). Conflicting results on gender distribution are reported concerning dementia with Lewy bodies (DLB), usually considered as an intermediate disease between AD and PD. The aim of the present study was to investigate gender differences in DLB in French specialized memory settings using data from the French national database spanning from 2010 to 2015 and to compare sex ratio in DLB with that in AD, Parkinson’s disease dementia (PDD), and PD. Our hypothesis was that there is a balanced sex ratio in DLB, different from that found in AD and PD. Methods We conducted a repeated cross-sectional study. The study population comprised individuals with a DLB, AD, PDD, or PD diagnosis according to the International Classification of Diseases, Tenth Revision, in the French National Alzheimer Database between 2010 and 2015. Sex ratio and demographic data were compared using multinomial logistic regression and a Bayesian statistical model. Results From 2010 to 2015 in French specialized memory settings, sex ratios (female percent/male percent) were found as follows: 1.21 (54.7%/45.3%) for DLB (n = 10,309), 2.34 (70.1%/29.9%) for AD (n = 135,664), 0.76 (43.1%/56.9%) for PD (n = 8744), and 0.83 (45.4%/54.6%) for PDD (n = 3198). Significant differences were found between each group, but not between PDD and PD, which had a similar sex ratio. Conclusions This large-sample prevalence study confirms the balanced gender distribution in the DLB population compared with AD and PD-PDD. Gender distribution and general demographic characteristics differed between DLB and PDD. This is consistent with the hypothesis that DLB is a distinct disease with characteristics intermediate between AD and PD, as well as with the hypothesis that DLB could have at least partially distinct neuropathological correlates.
Collapse
Affiliation(s)
- A Mouton
- Université Côte d'Azur, CobTeK lab, Nice, France. .,Centre Mémoire de Ressources et de Recherche, Institut Claude Pompidou, 10 rue Molière, 06100, Nice, France.
| | - F Blanc
- Geriatrics Department, University Hospitals of Strasbourg, CMRR (Research and Resources Memory Centre), Geriatric Day Hospital, Strasbourg, France.,University of Strasbourg and CNRS, ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), Team IMIS/Neurocrypto, Strasbourg, France
| | - A Gros
- Université Côte d'Azur, CobTeK lab, Nice, France
| | - V Manera
- Université Côte d'Azur, CobTeK lab, Nice, France
| | - R Fabre
- Université Côte d'Azur, CobTeK lab, Nice, France.,Centre Hospitalier Universitaire de Nice, Department of Public Health, L'Archet Hospital, Nice University Hospital, EA 6312, Nice, France
| | - E Sauleau
- University of Strasbourg and CNRS, ICube Laboratory UMR 7357, Strasbourg, France
| | | | - K Tifratene
- Université Côte d'Azur, CobTeK lab, Nice, France.,Antibes Hospital, Memory Center, Antibes, France
| | - L Friedman
- Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.,Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, Stanford University, Stanford, CA, USA
| | - S Thümmler
- Université Côte d'Azur, CobTeK lab, Nice, France.,Centre Hospitalier Universitaire de Nice, University Department of Child and Adolescent Psychiatry, Children's Hospitals CHU-Lenval, Nice, France
| | - C Pradier
- Centre Hospitalier Universitaire de Nice, Department of Public Health, L'Archet Hospital, Nice University Hospital, EA 6312, Nice, France
| | - P H Robert
- Université Côte d'Azur, CobTeK lab, Nice, France
| | - R David
- Université Côte d'Azur, CobTeK lab, Nice, France
| |
Collapse
|
11
|
Berman DJ, Knibbs N, Friedman L, Rocco M. Postpartum hemoptysis as presenting sign of longstanding vasculitis. Int J Obstet Anesth 2018; 36:122-125. [PMID: 30131261 DOI: 10.1016/j.ijoa.2018.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 07/11/2018] [Accepted: 07/24/2018] [Indexed: 11/16/2022]
Abstract
We present the case of a 26-year-old postpartum patient who presented with an episode of desaturation and hemoptysis on postpartum day three after an uncomplicated spontaneous vaginal delivery. The patient came to our attention in the postpartum area after she experienced massive hemoptysis and we were called by the obstetric team. The patient was subsequently intubated, mechanically ventilated, and underwent bronchoscopy, demonstrating diffuse alveolar hemorrhage. She was brought to the intensive care unit, placed on high-dose steroids and plasmapheresis was initiated. Her intensive care unit course was complicated by acute respiratory distress syndrome, acute kidney injury and a pulmonary embolism, but she recovered well and was discharged on postpartum day 23. This report describes a rare case of medium vessel vasculitis diagnosed in the peripartum period, and describes the diagnostic dilemmas underlying making a rare diagnosis, and the difficulties initiating appropriate therapy in a postpartum patient.
Collapse
Affiliation(s)
- D J Berman
- The Johns Hopkins Hospital Department of Anesthesiology and Critical Care Medicine, Baltimore, MD, United States.
| | - N Knibbs
- Icahn School of Medicine at Mount Sinai, Department of Anesthesiology, United States
| | - L Friedman
- Icahn School of Medicine at Mount Sinai, Department of Obstetrics and Gynecology, United States
| | - M Rocco
- Icahn School of Medicine at Mount Sinai, Department of Anesthesiology, United States
| |
Collapse
|
12
|
Goldstein-Piekarski AN, O’Hora K, Buchanan A, Lee C, Hernandez B, Zeitzer JM, Friedman L, Kushida C, Yesavage J. 0406 The Effects Of Cbt-i On Cognitive Functioning In Individuals With Insomnia And Mild Cognitive Impairment. Sleep 2018. [DOI: 10.1093/sleep/zsy061.405] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A N Goldstein-Piekarski
- Stanford University, Stanford, CA
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - K O’Hora
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - A Buchanan
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - C Lee
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - B Hernandez
- Stanford University, Stanford, CA
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - J M Zeitzer
- Stanford University, Stanford, CA
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | - L Friedman
- Stanford University, Stanford, CA
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| | | | - J Yesavage
- Stanford University, Stanford, CA
- Mental Illness Research Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA
| |
Collapse
|
13
|
Bonney T, Kyeremateng-Amoah E, Forst L, Friedman L. 1769c Acute occupational pesticide poisoning in illinois 2010–2015: data linkage of hospital discharge and poison control center databases. Epidemiology 2018. [DOI: 10.1136/oemed-2018-icohabstracts.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
Samant Y, Gravseth HM, Aas O, Ekle R, Strømholm T, Gigonzac V, Khireddine-Medouni I, Breuillard E, Bossard C, Guseva Canu I, Santin G, Chérié-Challine L, Bonney T, Kyeremateng-Amoah E, Forst L, Friedman L, Pesatori AC, Angelici L, Favero C, Dioni L, Mensi C, Bareggi C, Palleschi A, Cantone L, Consonni D, Bordini L, Todaro A, Bollati V. 1769 Occupational disease and morbidity modelling. Epidemiology 2018. [DOI: 10.1136/oemed-2018-icohabstracts.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
15
|
Blake RA, Hartman SJ, Kleinheinz TL, White J, Daly S, Goodwin R, Zhou W, Liang J, Wang X, O'Rourke M, Metcalfe C, Friedman L. Abstract P4-04-07: Characterization of the effects of estrogen receptor alpha Y537S and D538G mutations on receptor function and pharmacology. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-04-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The frontline therapy for estrogen receptor alpha (ERα) positive Breast Cancer (ER+BC) involves various forms of endocrine therapy, consisting of either Selective Estrogen Receptor Modulators (SERMs) or aromatase inhibitors. An emerging mechanism of ER+BC resistance to endocrine therapy, and consequently disease relapse, has been associated with a set of “hotspot” mutations in and near to helix-12 of the ERα ligand binding domain. Selective Estrogen Receptor Degraders/Down-regulators (SERDs), such as GDC-0810, AZD9496 and GDC-0927, represent a current major pharmacological strategy being applied to develop treatments for such resistant ER+BC. Here, we compare 2 of the most frequent ERα hotspot mutations (Y537S and D538G), with ERα wildtype (WT) and the ability of a set of ERα ligands (including GDC-0810, AZD9496 and GDC-0927) to bind, antagonize and degrade ERα. The concentration of each drug required to bind, antagonize or degrade ERα Y537S or ERα D538G was typically higher than that required for ERα WT. Importantly, ERα Y537S is resistant to estradiol stimulated protein degradation and 4-hydroxy-tamoxifen (a major active metabolite of tamoxifen) stabilizes ERα Y537S protein. This represents a potential mechanism of resistance of ERα Y537S ER+BC to Tamoxifen therapy.
Citation Format: Blake RA, Hartman SJ, Kleinheinz TL, White J, Daly S, Goodwin R, Zhou W, Liang J, Wang X, O'Rourke M, Metcalfe C, Friedman L. Characterization of the effects of estrogen receptor alpha Y537S and D538G mutations on receptor function and pharmacology [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-04-07.
Collapse
Affiliation(s)
- RA Blake
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - SJ Hartman
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - TL Kleinheinz
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - J White
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - S Daly
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - R Goodwin
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - W Zhou
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - J Liang
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - X Wang
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - M O'Rourke
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - C Metcalfe
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| | - L Friedman
- Genentech, South San Francisco, CA; Charles River Laboratories, Harlow, United Kingdom
| |
Collapse
|
16
|
Friedman L, Mcquary P, Shahbazian M, Ravuri S, Copeland K, Sheibani N, Hesterberg L. OA01.04 A Comparability Study Verifying the Analytic Performance of a Blood-based Gene Expression Classifier to Identify Benign Pulmonary Nodules. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Friedman L, Hernandez B, Buchanan A, Dinh M, Cooper B, Hou D, Posner D, Kushida C, Yesavage J, Zeitzer JM. 0346 COGNITIVE AROUSAL IN OLDER INDIVIDUALS WITH INSOMNIA COMPLAINTS AROUSAL IN OLDER INDIVIDUALS WITH INSOMNIA COMPLAINTS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Young A, Crocker L, Cheng E, Lacap J, Hamilton P, Oeh J, Ingalla E, Arrazate A, Hager J, Nannini M, Friedman L, Daemen A, Giltnane J, Sampath D. Abstract P4-06-05: Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is a key driver of hormone receptor (HR)–positive breast cancer growth and survival. It is estimated that 40-45% of HR+ breast cancers harbor oncogenic mutations in the PIK3CA gene, which encodes the p110α isoform of PI3K. Taselisib (GDC-0032) is a mutant-selective PI3K inhibitor that demonstrates enhanced potency in PIK3CA mutant breast cancer cells and is being developed as a treatment for metastatic breast cancer that targets PIK3CA-mutant, HR-positive, HER2-negative patients. Activating mutations in the ESR1 gene were recently described in metastatic breast cancer. These mutations confer hormone independent growth and may be associated with resistance to aromatase inhibitors. Drugs that selectively bind and antagonize the Estrogen Receptor alpha (ERα) protein and target it for degradation, such as fulvestrant, are referred to as selective estrogen receptor degraders (SERDs). Preclinical activity of the orally bioavailable SERD, GDC-0810, has not been well characterized in ESR1 mutant PDX models. Therefore, our aim was to evaluate the efficacy and pharmacodynamic responses to agents that target ERα and PI3K as monotherapies and in combination, in ESR1 and PIK3CA mutant HR+ breast cancer patient-derived xenograft (PDX) models. We hypothesized that mutational status of ESR1 and PIK3CA may predict the responsiveness of HR+ PDX models to SERDs and PI3K inhibitors in vivo. Characterization of seven PDX models included authentication of hormone receptor status by immunohistochemistry (IHC) and determination of ESR1 and PIK3CA genotype and allele frequency by exome sequencing. For a subset of models that utilize estrogen for growth, mice were supplemented with 17β-estradiol, and cells or tumor fragments were implanted into the fat pad of intact female NOD-SCID or NOD-SCID-IL2Rgamma null mice and treated with fulvestrant, GDC-0810, or taselisib. Both fulvestrant and GDC-0810 were efficacious in ESR1 wild type (WT) and mutant PDX models but to variable degrees ranging from tumor stasis to growth delay, with GDC-0810 resulting in superior single agent activity at relevant clinical exposure in the WHIM20 and WHIM43 ESR1 mutant models. PIK3CA mutations (E542K, E545K, M1004V, and H1047R) were confirmed in six PDX models and PI3K pathway activation verified by strong pS6RP IHC staining. Taselisib induced tumor growth inhibition and tumor regressions in models harboring PIK3CA mutations, and models with no detectable expression of WT p110α were the most sensitive. In the WHIM43 (ESR1 D538G, PIK3CA M1004V), HCI-011 (ESR1 WT, PIK3CA E545K) and HCI-013 (ESR1 Y537S, PIK3CA H1047R) PDX models, combining fulvestrant and taselisib treatment further enhanced tumor growth inhibition with respect to either treatment alone. Our studies demonstrate the diverse anti-tumor responses of HR+ PDX models to SERDs and the PI3K inhibitor taselisib in the context of clinically relevant ESR1 and PIK3CA mutations. Pharmacological and genomic characterization of additional PDX models may aid in strengthening associations between genotype, drug sensitivity and predictive biomarkers of response.
Citation Format: Young A, Crocker L, Cheng E, Lacap J, Hamilton P, Oeh J, Ingalla E, Arrazate A, Hager J, Nannini M, Friedman L, Daemen A, Giltnane J, Sampath D. Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-06-05.
Collapse
Affiliation(s)
- A Young
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - L Crocker
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - E Cheng
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Lacap
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - P Hamilton
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Oeh
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - E Ingalla
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - A Arrazate
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Hager
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - M Nannini
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - L Friedman
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - A Daemen
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Giltnane
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - D Sampath
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| |
Collapse
|
19
|
Chapman KB, Copeland K, Kidd J, Qiu L, Sheibani N, Tam O, Friedman L, Korn R, Fiorica J, Lourenco A, Suthers S, Hesterberg L. Abstract P5-03-05: Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-03-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Current breast cancer screening guidelines call for annual mammography for asymptomatic women age 45 to 54 and once every two years for women age 55 and older. Women with suspicious screening mammograms are recommended for a diagnostic mammogram and may also undergo MRI or ultrasound. Ultimately, suspicious findings unresolved by imaging typically result in the recommendation of a breast biopsy. Approximately 10% of suspicious diagnostic mammograms are recommended for breast biopsies and 67% to 95% of these biopsies yield negative results. With the goal of reducing the number of patients with benign pathology undergoing invasive biopsies, we conducted a screen for serum protein biomarkers and identified a novel panel for the non-invasive detection of breast cancer.
Methods: Serum samples were collected at two sites from women with suspicious diagnostic mammogram findings (primarily BI-RADS category 4) undergoing biopsy for the evaluation of a potential malignancy. Serum samples from 100-patients (50 benign pathology and 50 malignant pathology) were evaluated on the SOMAscan Assay 1.3k, which measures levels of 1,310 different protein analytes. Statistical screening methodologies, such as individual t-tests with control for false discovery, were used to identify markers with the potential to distinguish benign from malignant pathology. The candidate markers were further studied and combined using generalized linear modeling to develop three potential diagnostic models. K-fold cross validation was used to guard against over fitting of the models.
Results: A 15-marker model resulted in an AUC of 0.92 with a sensitivity of 90% and specificity of 76%. Two 6-marker models (with 4 markers in common) each resulted in AUC of 0.85, yielding a sensitivity of 90% with a specificity of 56% or 64%.
Conclusions: This study reveals a novel panel of serum protein biomarkers that may allow for the non-invasive and sensitive detection of breast cancer in BI-RADS category 4 patients. A multicenter study is underway to further refine and validate this panel in a larger set of prospectively collected patient samples.
Citation Format: Chapman KB, Copeland K, Kidd J, Qiu L, Sheibani N, Tam O, Friedman L, Korn R, Fiorica J, Lourenco A, Suthers S, Hesterberg L. Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-03-05.
Collapse
Affiliation(s)
- KB Chapman
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - K Copeland
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - J Kidd
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - L Qiu
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - N Sheibani
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - O Tam
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - L Friedman
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - R Korn
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - J Fiorica
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - A Lourenco
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - S Suthers
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| | - L Hesterberg
- OncoCyte Corporation, Alameda, CA; Boulder Statistics, Boulder, CO; Scottsdale Medical Imaging, Scottsdale, AZ; Sarasota Memorial Hospital, Sarasota, FL; Rhode Island Hospital, Providence, RI; Mercy Clinic Oncology, Oklahoma City, OK
| |
Collapse
|
20
|
De PK, Carlson JH, Sun Y, Lin X, Friedman L, Dey N, Leyland-Jones B. Abstract P6-03-01: A combination of dual inhibition in HER2-network by T-DM1 and GDC-0980 provides maximal antitumor efficacy in preclinical model of HER2+ breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-03-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PIK3CA mutation is associated with a lower pCR rate in primary HER2+ breast cancer (BC) treated with trastuzumab and lapatinib in addition to chemotherapy (from five clinical trials, PMID: 27177864). The BOLERO-1 study showed that the efficacy of a combination of mTOR inhibitor (everolimus) plus trastuzumab (T) and paclitaxel was not very efficacious with HER2+ advanced BC patients except for HER2+/ER- BC patients (PMID: 26092818). In the same line, BOLERO 3 trial data showed the same combination (T + everolimus + vinorelbine) is also not efficacious in T-resistant, HER2+ advanced breast cancer women (median PFS 7 months with everolimus and 5.78 months with placebo, HR: 0.78) (PMID: 24742739). T-DM1 does not have typical adverse events of chemotherapy. Therefore, there has been interest in combining it with other targeted agent. Here we tested the efficacy of a combination of T-DM1 plus GDC-0980 (a dual PI3K/mTOR inhibitor) in HER2+/T-resistant BC cell lines in vitro and in vivo. Methodology: Here we have studied the in vitro and in vivo effects of GDC-0980 along with T-DM1 in HER2+/T-sensitive (BT474), HER2+/T-resistant (BT474HerR), and HER2+/PIK3CA (HCC1954, MDA-MB453) mutated models. We assessed in vitro anti-proliferative, pro-apoptotic and activation status of the PI3K-AKT-mTOR signaling pathway following the combination of GDC-0980 plus T-DM1 in HER2+ BC cell lines. We next evaluated the impact of GDC-0980 plus T-DM1 on tumor growth and angiogenesis using xenograft models. Results: 1) GDC-0980 inhibited downstream activation of the PI3K-mTOR signaling pathway effectors, p-AKT (Ser473, The308), p-P70S6K, p-S6RP and p-4EBP1, and this inhibition was more pronounced when GDC-0980 was combined with T-DM1, 2) similarly the anti-proliferative activity of a combination of GDC-0980 plus T-DM1 was significantly higher by 3D-ON-TOP clonogenic assay following heregulin stimulation, 3) consistent with anti-proliferative effects of GDC-0980, the proportion of cells in the G1 phase of the cell cycle increased in HER2+ cell lines with a concomitant decrease in the S phase of their treatment with GDC-0980, 4) the initiation of apoptotic activity (annexin V) of GDC-0980 was significantly superior to that of an allosteric inhibitor of mTOR, RAD001. GDC-0980 also induced apoptotic markers like cleaved CASPASE3, cleaved PARP1, BIM in HER2+ BC cells and 5) a combination of GDC-0980 plus T-DM1 significantly blocked tumor growth to tumor regression in the HER2+/T-sensitive, HER2+/T-resistant and HER2+/PIK3CA mutated BC xenograft models. Along with its anti-tumor effect, this combination effectively decreased tumor angiogenesis (tumor micro-vessel density via CD31 staining). Conclusions: A combination of GDC-0980 plus T-DM1 significantly blocked in vitro and in vivo HER2+ breast tumor cells growth irrespective of PIK3CA mutation status. This strategy warrants further clinical investigation.
Citation Format: De PK, Carlson JH, Sun Y, Lin X, Friedman L, Dey N, Leyland-Jones B. A combination of dual inhibition in HER2-network by T-DM1 and GDC-0980 provides maximal antitumor efficacy in preclinical model of HER2+ breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-03-01.
Collapse
Affiliation(s)
- PK De
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - JH Carlson
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - Y Sun
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - X Lin
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - L Friedman
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - N Dey
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| | - B Leyland-Jones
- Avera Center for Precision Oncology, Sioux Falls, SD; Genentech Inc., SF, CA
| |
Collapse
|
21
|
Stolz L, Gaskin K, Murphy A, Conroy K, Stears-Ellis S, Javedani P, Friedman L, Adhikari S. 363 Sonographic Appearance of Peripheral Nerves: Visualizing Success. Ann Emerg Med 2016. [DOI: 10.1016/j.annemergmed.2016.08.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Carlson JH, Krie A, Williams C, Sun Y, Lin X, Williams K, Klein J, Friedman L, De P, Dey N, Leyland-Jones B. Abstract P4-08-04: Navigating genomic landscape to find a PI3K-signaling algorithm for a rational combinatin in precision medicine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-08-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment of BC is conventionally based on the presence/absence of ER/PR or HER2 status of the primary tumor. We have enriched this approach by including major genetic and proteomic changes in tumors of individual patients in order to develop a better treatment-rationale based on an alteration driven signaling algorithm. Methods: Genomic and proteomic data from 75 BC patients seen in our center were retrospectively analyzed. Patients were re-biopsied after consultation and samples were characterized (IHC for ER, PR, and HER2; FFPE samples for genomic [Foundation Medicine] and proteomic analyses [Theranostics]). In vivo studies were conducted using xenograft models. Results: Although alterations of PIK3CA, PIK3R1, AKT, PTEN, MDM2, MDM4, TSC1, mTOR and RICTOR are most frequently observed in our patients, there is a distinct pattern of alteration(s) of the PI3K pathway genes in different subtypes of BC. A total of 76 genes were altered in 48 ER+BC patients. In 79% of ER+BC patients the above mentioned PI3K pathway genes were altered. Analyzing the set of alterations of genes in individual patients, we observed that within these 48 patients 25% exhibited alterations in more than one node of the pathway; the most common combination (alterations) being the amplification/mutation of PIK3CA with the amplification of MDM2/4 genes. The percentage of patients belonging to HER2+ & TNBC exhibiting similar alterations in the PI3K pathway genes were significantly lower (∼40%). Our previous in vivo studies demonstrated that GDC-0980 and BEZ235 enhanced the antitumor activity of ABT888 plus carboplatin in TNBC or trastuzumab in HER2+ BC respectively and blocked the growth of established xenograft tumors by 80% to 90% with a concomitant decrease in tumor Ki67, pS6RP and CD31. Mechanistically the action of the PI3K-mTOR pathway targeted drug(s) was tested using cell line based models of BC subtypes pertaining to their respective genomic alterations. A combination of a pan-PI3K pathway inhibitor, GDC-0941 or isoform-specific inhibitors along with AI, trastuzumab, or HRD inhibitors (PARP) blocked proliferative signals and enhanced apoptosis (cleaved caspase3) in ER+/PIK3CA mutated, HER2+/PIK3CA mutated or PTEN-null TNBC cells respectively as demonstrated by WB, flow cytometry, cell proliferation, viability and cytotoxicity assays. A recent study demonstrated that exposure to chemotherapy induced a phenotypic shift or cell state transition towards a transient CD44Hi/CD24Hi chemotherapy-tolerant state, leading to the activation of downstream non-receptor tyrosine kinase signaling towards an emerging adaptive resistance (Goldman et al., Nature Comm. 2015). Hence drug combination(s) are being tested for their effect on CD44/CD24 expression levels, results of which will be presented in the meeting. Conclusion: Plotting the genetic alterations from the patient on the signaling landscape will be useful in cracking the code leading to improved treatment options. Patient specific in-depth plotting of genetic alterations of the PI3K-mTOR pathway and the relevance of these alterations in the context of (1) mechanisms of PI3K-mTOR pathway targeted drugs and (2) cell signaling are critical in determining choice of drugs in BC subtypes.
Citation Format: Carlson JH, Krie A, Williams C, Sun Y, Lin X, Williams K, Klein J, Friedman L, De P, Dey N, Leyland-Jones B. Navigating genomic landscape to find a PI3K-signaling algorithm for a rational combinatin in precision medicine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-08-04.
Collapse
Affiliation(s)
- JH Carlson
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - A Krie
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - C Williams
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - Y Sun
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - X Lin
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - K Williams
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - J Klein
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - L Friedman
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - P De
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - N Dey
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| | - B Leyland-Jones
- Avera Cancer Institute, Sioux Falls, SD; Genentech, San Francisco, CA
| |
Collapse
|
23
|
Ong CC, Blackwood E, Jakubiak D, Daemen A, Ramaswamy S, Heise C, Schmidt M, Sanders L, Wilson TR, Huw L, Ndubaku C, Rudolph J, Hoeflich KP, Friedman L, O'Brien T. Abstract PD3-04: PAK-1 amplified breast cancer cell lines are preferentially sensitive to PAK inhibition with G-5555. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd3-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The small GTP-binding proteins Rac1 and Cdc42 stimulate activity of the serine/threonine kinase p21-activated kinase-1 (PAK-1) to drive growth factor signaling networks and Ras-driven tumorigenesis. Genomic amplification and over-expression of PAK1 are prevalent in luminal breast cancer and correlate with poor clinical outcome. Here we use a novel and selective small molecule inhibitor, G-5555, of the group I PAKs (PAK1, 2, and 3) to evaluate the importance of PAK1 in promoting growth of PAK1 amplified breast cancer cells. Cell lines with amplification of PAK1 were found to be more sensitive to PAK1 inhibition than non-amplified cell lines. Additionally, reverse phase protein array (RPPA) was used to assess the effects of PAK1 inhibition on a wide range of signaling pathways in both amplified and non-amplified cell lines. Reduced levels of phosphorylation of MEK S298 was observed in all cell lines exposed to G-5555 irrespective of amplification status, consistent with PAK1 inhibition in these cell lines. However, modulation of this downstream PAK1 substrate did not correlate with inhibition of cell proliferation or induction of cell death. Cell lines that showed inhibition of proliferation in response to G-5555 also showed enhanced levels of cell death along with apoptosis. Moreover, G-5555 reduced tumor growth in the PAK1 amplified MDA-MB-175 xenograft tumor model. Finally, we compared the in vitro activity of G-5555 with palbociclib, a recently approved inhibitor of the cyclin-dependent kinases CDK4 and CDK6, in PAK1 amplified luminal breast cancer cell lines. Our data supports PAK1 as an attractive target in PAK1 amplified cells and tumors and suggests that inhibiting PAK1 rather than CDK4/6 in this context may be a more attractive therapeutic strategy.
Citation Format: Ong CC, Blackwood E, Jakubiak D, Daemen A, Ramaswamy S, Heise C, Schmidt M, Sanders L, Wilson TR, Huw L, Ndubaku C, Rudolph J, Hoeflich KP, Friedman L, O'Brien T. PAK-1 amplified breast cancer cell lines are preferentially sensitive to PAK inhibition with G-5555. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD3-04.
Collapse
Affiliation(s)
- CC Ong
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - E Blackwood
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - D Jakubiak
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - A Daemen
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - S Ramaswamy
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - C Heise
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - M Schmidt
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - L Sanders
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - TR Wilson
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - L Huw
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - C Ndubaku
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - J Rudolph
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - KP Hoeflich
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - L Friedman
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| | - T O'Brien
- Genentech, Inc, South San Francisco, CA; Blueprint Medicines, Cambridge, MA
| |
Collapse
|
24
|
Gay IC, Tran DT, Weltman R, Parthasarathy K, Diaz‐Rodriguez J, Walji M, Fu Y, Friedman L. Role of supportive maintenance therapy on implant survival: a university‐based 17 years retrospective analysis. Int J Dent Hyg 2015; 14:267-271. [DOI: 10.1111/idh.12188] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/10/2015] [Indexed: 11/27/2022]
Affiliation(s)
- IC Gay
- Department of Periodontics East Carolina University GreenvilleNCUSA
| | - DT Tran
- Department of Diagnostics and Biomedical Sciences School of Dentistry University of Texas Houston TX USA
| | - R Weltman
- Department of Periodontics and Dental Hygiene School of Dentistry University of Texas Houston TX USA
| | - K Parthasarathy
- Department of Periodontics and Dental Hygiene School of Dentistry University of Texas Houston TX USA
| | - J Diaz‐Rodriguez
- Department of Periodontics and Dental Hygiene School of Dentistry University of Texas Houston TX USA
| | - M Walji
- Department of Diagnostics and Biomedical Sciences School of Dentistry University of Texas Houston TX USA
| | - Y Fu
- Human Genetics Center Division of Biostatistics School of Public Health University of Texas Houston TX USA
| | - L Friedman
- Department of Periodontics and Dental Hygiene School of Dentistry University of Texas Houston TX USA
| |
Collapse
|
25
|
Buchanan S, Stapleton G, Friedman L, Loy G, Bashook P. Promoting healthy fish consumption to reduce perinatal exposure to mercury. Fertil Steril 2015. [DOI: 10.1016/j.fertnstert.2015.07.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Merchant M, Chan J, Orr C, Cheng J, Wang X, Hunsaker T, Wagle M, Huang S, Tremayne J, Ngu H, Solon M, Eastham-Anderson J, Koeppen H, Friedman L, Belvin M, Moffat J, Junttila M. 387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70513-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
27
|
Schöffski P, Li H, Wozniak A, Cornillie J, Wellens J, Van Looy T, Hompes D, Friedman L, Sciot R, Debiec-Rychter M. Efficacy of Combined Pi3K and Angiogenesis Inhibition in Dedifferentiated Liposarcoma (Ddlps). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu358.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Dey N, Sun Y, Carlson J, Friedman L, De P, Leyland-Jones B. Abstract P3-04-02: Absence of PTEN facilitates the anti-tumor efficacy of GDC-0980 in combination with ABT888 plus carboplatin in BRCA1-competent triple negative breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: PI3K pathway, in addition to its pro-proliferative and anti-apoptotic effects on tumor cells, is known to contribute to DNA-damage repair (DDR). We hypothesized that GDC-0980, a dual PI3K-mTOR inhibitor, will induce an efficient anti-tumor effect in BRCA-competent PTEN-null TNBC cells when combined with PARP inhibitor, ABT888 and carboplatin. We propose that in PTEN-null BRCA-competent TNBC model, the growth of TNBC tumor will be blocked due to the inhibition of (1) HR and NHEJ and (2) PI3K-mTOR pathway mediated survival signals following treatment with GDC-0980, when combined with PARP inhibitor (impaired DNA-SSB-repair) and carboplatin (increased DNA-DSB). Purpose: Here we tested the efficacy of a combination of GDC-0980 with ABT888 plus carboplatin in BRCA-competent PTEN-null model of TNBC. Methods: Athymic mice bearing PTEN-null TNBC xenograft tumors were treated with GDC-0980 alone or in combination with ABT888 and carboplatin. Results: Dual inhibition of PI3K and mTOR by GDC-0980 alone as well as in the presence of carboplatin plus ABT888 changed the state of the repair of DNA-damage in BRCA-competent PTEN null TNBC cells, which led to increased cellular apoptotic signals in addition to decreased survival/proliferative signals. GDC-0980 treatment led to DNA damage (increased pgH2AX), gain in PAR and a subsequent sensitization of BRCA-competent PTEN-null MDA-MB468 TNBC cells to ABT888 plus carboplatin with a time-dependent (1) decrease in proliferation signals (pAKT T308/S473, pP70S6K, pS6RP), PAR/PARP ratios, PAR/pgH2AX ratios, live/dead cell ratios, cell-cycle progression and clonogenic 3D growth and (2) increase in apoptosis markers (cleaved-caspase 3, 9, BIM, cleaved-PARP and annexinV positivity). These effects are more pronounced in MDA-MB468 than in RAS/RAF mutated MDA-MB231 cells. GDC-0980 alone and in combination with ABT888 plus carboplatin inhibited cell cycle progression, increased apoptosis, and decreased live/dead cell ratios in BRCA-competent PTEN null TNBC cells. GDC-0980 alone and in combination with ABT888 plus carboplatin attenuated anchorage -dependent and -independent clonogenic 3D growth comparatively more in BRCA-competent PTEN-null cells TNBC cells than MDA-MB231 cells. GDC-0980 in combination with ABT888 plus carboplatin blocked the growth of established PTEN-null TNBC tumors as compared to vehicle control(s) with a concomitant decrease in tumor Ki67 and CD31 IHC-stains. Conclusion: This is the first mechanism-based study to demonstrate that in BRCA-competent PTEN-null TNBC model, GDC-0980 enhanced antitumor activity of ABT888, in the presence of carboplatin by inhibiting DDR system in conjunction with the inhibition of PI3K-mTOR pathway-mediated proliferative, and anti-apoptotic signals. Considering (1) the importance of PARP as the target in TNBC, (2) the existence of a large percentage of BRCA-competent TN and/or basal type BC patients and (3) the high frequency of PTEN-null-ness in this subset of BC, this combination merits further investigation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-04-02.
Collapse
Affiliation(s)
- N Dey
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| | - Y Sun
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| | - J Carlson
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| | - L Friedman
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| | - P De
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| | - B Leyland-Jones
- Edith Sanford Breast Cancer Research/Sanford Research/USD, Sioux Falls, SD; Genetech Inc, San Fransisco, CA
| |
Collapse
|
29
|
Savage H, O'Brien C, Spoerke J, Huw L, Wallin J, Friedman L, Lackner MR, Wilson TR. Abstract P6-05-09: Development of a predictive biomarker gene expression signature for the PIK3CA inhibitor, GDC-0032, in breast cancer cells. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-05-09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
The PI3-Kinase pathway is one of the most commonly mutated pathways in cancer and plays a major role in cell proliferation and survival. Mutations in PIK3CA, the gene encoding the p110 subunit of PI3K, are among the most common alterations in breast cancer, occurring in approximately 45% of luminal A, 30% of luminal B, 30% of HER2 positive and 8% of triple negative breast cancers. Additional pathway activating alterations include loss of PTEN, AKT mutations and overexpression of PIK3CA and HER2. Development of a pharmacodynamic biomarker is challenging with the more isoform specific PI3K inhibitors as multiple upstream pathways can funnel into common downstream immunohistochemical evaluable endpoints. In addition, phosphorylated epitopes are often labile and do not always lend themselves to immunohistochemical evaluation in the clinical setting. GDC-0032, which is currently under clinical investigation, is a class I PI3K inhibitor with 30-fold less inhibition on PI3K beta relative to PI3K alpha, and the development of a predictive and on-study pharmacodynamic signature may prove informative as compared to traditional IHC endpoints.
Methods
We screened a panel of 53 breast cancer cell lines, incorporating all subtypes, to GDC-0032 using the cell proliferation assay cell titer glo. To determine if there was a relationship between pathway activation and sensitivity to GDC-0032, we correlated response to PIK3CA mutations, loss of PTEN and HER2 overexpression. Using RNA sequencing, we compared the baseline gene expression between the sensitive and refractory cell lines. Next, to identify an on-study pharmacodynamic gene expression signature, we treated both sensitive and refractory cell lines with GDC-0032 and ran an in-house custom designed 800 gene NanoString breast cancer gene set that incorporated published PI3K pathway signatures, intrinsic subtyping genes and immunological related genes. Finally, the GDC-0032 signature was applied to a set of 160 FFPE breast cancer samples and overlaid with relevant biomarkers.
Results and Conclusions
Sensitivity to GDC-0032 correlated strongly with PI3K pathway activation including PIK3CA mutations and HER2 overexpression in breast cancer cells. Comparing baseline whole genome RNA expression of GDC-0032 sensitive and refractory cell lines, we identified 293 genes that were differentially expressed. Applying a more stringent statistical cutoff (greater than 2 fold difference and t-test less than 0.01) refined the gene list to 51 genes, which defined the baseline GDC-0032 sensitivity signature. Applying the 800 gene breast cancer NanoString panel to a set of 160 FFPE breast cancer samples, the GDC-0032 sensitivity signature correlated with luminal status and was enriched in PIK3CA mutant tumors. In conclusion, our in-house designed GDC-0032 sensitivity signature correlated strongly with PIK3CA mutations in clinical specimens. However the lack of complete correlation may identify tumors that have an activated PI3K pathway outside of PIK3CA mutations and/or HER2 amplification that may derive clinical benefit from GDC-0032.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-05-09.
Collapse
Affiliation(s)
- H Savage
- Genentech, South San Francisco, CA
| | | | | | - L Huw
- Genentech, South San Francisco, CA
| | - J Wallin
- Genentech, South San Francisco, CA
| | | | | | | |
Collapse
|
30
|
De P, Sun Y, Carlson J, Friedman L, Dey N, Leyland-Jones B. Abstract P5-06-01: The PI3K inhibitor GDC-0941 combines with trastuzumab for superior anti-tumor efficacy in HER2+ breast cancer models. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PI3K-AKT-mTOR pathway signaling is important for the oncogenic function of HER2. Activating alterations of this pathway are frequently observed in HER2-enriched breast cancer and generally herald a poor response and resistance to trastuzumab (T). Purpose: Targeting the PI3K-AKT-mTOR pathway is an attractive strategy in HER2+ breast cancer that is refractory to trastuzumab. The hypothesis is that the suppression of this pathway by pan-PI3K inhibitor, GDC-0941 may lead to overcome trastuzumab-resistance. Experimental Design: The antiproliferative and HER2-mediated cellular signaling (pAKT, pP70S6K, pS6RP, p4EBP1 and p-ERK) effects of GDC-0941 alone and in combination with T were evaluated in HER2 amplified T-sensitive (BT474), T-resistant (BT474HR), and HER2 amplified/PIK3CA mutated (HCC1954, UACC893) BT cell lines by MTT assay and Western blots. Clonogenic growth was tested by 3D ON-TOP assay and apoptosis markers were also tested. Athymic mice bearing BT474 and BT474HR xenograft tumors were treated with GDC-0941 and T (alone and in combination). Results: (1) GDC-0941 exhibited in vitro cell killing activity in MTT assay with IC50's ranging from 0.35 μM to 1 μm and potency was augmented by the addition of T, (2) inhibition of phosphorylation of AKT(S473, T308), P70S6K, S6RP, and 4EBP1(T37/46, T70) was observed following GDC-0941 treatment, and the combination of GDC-0941 and T more effectively blocked the PI3K-AKT-mTOR pathway, (3) GDC-0941 treatment increased apoptosis markers (CL-CASPASE3 and annexinV positivity), (4) GDC-0941 dose-dependently blocked 3D-ON-TOP clonogenic growth of HER2+ cells. This effect was potentiated in the presence of T and (5) in vivo, the combination of GDC-0941 and T significantly reduced established tumor growth in both sensitive (82%) and resistant (79%) models with concomitant decrease of different PD markers. Conclusions: Our data suggest that 1) therapeutic targeting of the PI3K-AKT-mTOR signaling should be effective in abrogating resistance to T therapy in HER2+ BT, and 2) targeting both the HER2 and the PI3K signaling pathways is an attractive strategy to enhance the clinical efficacy of T therapy, as well as to prevent or delay the development of resistance.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-06-01.
Collapse
Affiliation(s)
- P De
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| | - Y Sun
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| | - J Carlson
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| | - L Friedman
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| | - N Dey
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| | - B Leyland-Jones
- Sanford Research, Sioux Falls, SD; Genentech, San Fransisco, CA
| |
Collapse
|
31
|
Friedman L, Ross LB, Wallin J, Guan J, Prior WW, Wu E, Nannini M, Sampath D. Abstract P5-19-02: Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-19-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Phosphoinositide 3-kinases (PI3K) are lipid kinases that can regulate breast tumor cell growth, migration and survival. Standard of care drugs such as estrogen receptor (ER) antagonists including fulvestrant and tamoxifen, and aromatase inhibitors such as letrozole are indicated for the treatment of hormone receptor positive breast cancer. The current study is focused on investigating preclinical activity in breast cancer models, for GDC-0941, a class I PI3K inhibitor, GDC-0032, a PI3K inhibitor, and GDC-0980, a dual mTOR kinase and class I PI3K inhibitor. Investigation into PI3K inhibitor efficacy in combination with endocrine therapies is also explored.
Experimental Design: A panel of ER+ breast cancer cell lines were treated with GDC-0941, GDC-0032 and GDC-0980 either as single agents or in combination with fulvestrant or tamoxifen and assayed for cellular effects. MCF-7 cells ectopically expressing aromatase were utilized to test the efficacy of aromatase inhibitors in combination with PI3K inhibitors in vitro. In addition, human xenografts of breast cancer cell lines were employed to assess combination efficacy of PI3K inhibitors with fulvestrant and tamoxifen in vivo.
Results: Combination of GDC-0941, GDC-0032 or GDC-0980 with endocrine therapies resulted in a decrease in cellular viability and an increase in cell death. Synergy of PI3K inhibitor combinations with fulvestrant or tamoxifen was assessed using Combination Index (C.I.), and C.I. values as low as 0.1 indicated strong synergy in some contexts. Combination activity of PI3K inhibitors and letrozole was also observed in MCF7 cells expressing aromatase. In MCF-7 xenografts, the combination of GDC-0980, GDC-0032 and GDC-0941 enhanced activity of fulvestrant resulting in tumor regressions and tumor growth delay (116% tumor growth inhibition (TGI) for GDC-0980 and 91% TGI for GDC-0941 and GDC-0032). In addition, the combination of GDC-0941 or GDC-0032 with tamoxifen enhanced the efficacy of tamoxifen in vivo (83%TGI for GDC-0941 and 102%TGI for GDC-0032). Mechanism of action and biomarker studies are underway.
Conclusion: Collectively, the non-clinical efficacy data provide a strong rationale to evaluate the combination of PI3K inhibitors with anti-estrogen therapy in hormone receptor positive breast cancer.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-19-02.
Collapse
Affiliation(s)
- L Friedman
- Genentech, Inc., South San Francisco, CA
| | - LB Ross
- Genentech, Inc., South San Francisco, CA
| | - J Wallin
- Genentech, Inc., South San Francisco, CA
| | - J Guan
- Genentech, Inc., South San Francisco, CA
| | - WW Prior
- Genentech, Inc., South San Francisco, CA
| | - E Wu
- Genentech, Inc., South San Francisco, CA
| | - M Nannini
- Genentech, Inc., South San Francisco, CA
| | - D Sampath
- Genentech, Inc., South San Francisco, CA
| |
Collapse
|
32
|
|
33
|
Dutour A, Jury D, Restagno D, Decouvelaere A, Belvin M, Friedman L, Michot J, Blay J. 43 Targeting the PI3K/mTOR Pathway for Sarcoma Treatment: Investigation in Rat Syngeneic Chondrosarcoma Model. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71841-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
34
|
Hatzivassiliou G, Haling J, Chen H, Song K, Peck A, Hoeflich K, Friedman L, Malek S, Belvin M. 378 Differential Targeting of KRAS and BRAF Mutant Tumors Using MEK Inhibitors with Distinct Mechanisms of Action. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72176-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
35
|
Holloway-Beth A, Friedman L. Using National Injury Surveillance Systems to Assess Law Enforcement-Related Injury and Fatality Rates. Ann Epidemiol 2012. [DOI: 10.1016/j.annepidem.2012.06.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
36
|
Badjatia N, Monahan A, Carpenter A, Friedman L, Zimmerman J, Schmidt JM, Claassen J, Lee K, Connolly S, Mayer S, Karmally W, Seres D. Impact of Underfeeding and Protein Catabolism on Hospital-Acquired Infections after Subarachnoid Hemorrhage (S19.004). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s19.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
|
38
|
Belvin M, Berry L, Chan J, den Otter D, Friedman L, Hoeflich K, Koeppen H, Merchant M, Orr C, Rice K. 132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71837-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
39
|
Friedman L, Belvin M, Berry L, Haverty P, Hoeflich K, Lackner M, Sampath D, Wallin J, Yauch B. 142 GDC-0941 PI3K inhibitor activity in preclinical lung cancer models. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71847-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Salphati L, Lee L, Pang J, Plise E, Zhang X, Nishimura M, Friedman L, Sampath D, Phillips H. 133 Role of Abcb1 (P-glycoprotein) and Abcg2 (Bcrp1) in the brain penetration of the novel PI3K Inhibitor GDC-0941 and efficacy in orthotopic xenograft models of glioblastoma and metastasis. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)71838-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
41
|
Ledbetter MC, Beuhler RJ, Friedman L. "Cluster-ion" bombardment of biological macromolecules: Morphological evidence for disassembly of single tobacco mosaic virus particles. Proc Natl Acad Sci U S A 2010; 84:85-8. [PMID: 16593795 PMCID: PMC304146 DOI: 10.1073/pnas.84.1.85] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Cluster ions containing 50, 100, or 200 water molecules and one proton are accelerated to over 275 kV and impacted on thin carbon films on which tobacco mosaic virus has been dispersed. After bombardment the films are examined with a transmission electron microscope to study induced morphological alterations with respect to the energy transfer processes that take place during and after single cluster-ion impact. Observations on tobacco mosaic virus indicate that a single cluster impact results in the removal of a cylindrical segment of the virus. No fragments from the excised TMV segment were observed on the carbon foil. We speculate that cluster-ion bombardment may become a useful analytical technique for structural studies of large biological macromolecular complexes.
Collapse
Affiliation(s)
- M C Ledbetter
- Biology Department, Brookhaven National Laboratory, Upton, NY 11973
| | | | | |
Collapse
|
42
|
David R, Zeitzer J, Friedman L, Noda A, O'Hara R, Robert P, Yesavage JA. Non-pharmacologic management of sleep disturbance in Alzheimer's disease. J Nutr Health Aging 2010; 14:203-6. [PMID: 20191254 DOI: 10.1007/s12603-010-0050-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Sleep and wake in Alzheimer's disease (AD) are often fragmented as manifested by bouts of wakefulness at night and napping during the day. Management of sleep disturbances in AD is important because of their negative impact on both patients and caregivers. Pharmacological treatments, mainly sedative-hypnotics and antipsychotics, are often used but can be associated with significant adverse effects. Non-pharmacological treatments represent a beneficial alternative approach to the management of sleep disturbances in AD since they are associated with fewer adverse effects and their efficacy can be sustained after treatment has been completed. The aim of this article is to review non-pharmacological treatments, such as sleep hygiene, sleep restriction therapy (SRT), cognitive behavioral therapy (CBT), light therapy, and continuous positive airway pressure (CPAP), for the management of sleep/wake disturbances in AD.
Collapse
Affiliation(s)
- R David
- Department of Veterans Affairs Health Care System, Palo Alto, California 94304, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Rudick B, Friedman L, Chung K, Paulson R, Bendikson K. The Progression of Endometrial Polyps in an Infertile Population. Fertil Steril 2009. [DOI: 10.1016/j.fertnstert.2009.01.167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
44
|
Friedman L, Belvin M, Le Couter J, Lin K, Robillard L, Sampath D, Stern H, Vijapurkar U, Ye W, Plowman G. 227 POSTER Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72159-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
45
|
Abstract
The decision in a Scottish smoker's case, McTear v. Imperial Tobacco Limited, that there was no scientific proof of causation between the plaintiff's smoking and his death from lung cancer, accepted all of the traditional arguments that the tobacco industry has made throughout the history of tobacco litigation, including that epidemiology is not an adequate branch of science to draw a conclusion of causation, that the tobacco industry has no knowledge that its products are dangerous to consumers, and that, despite this lack of knowledge, the plaintiff had sufficient information to make an informed decision about the dangers of smoking. This case relied on outmoded methods of reasoning and placed too great a faith in the tobacco industry's timeworn argument that "everybody knew, nobody knows". Further, the judge found it prejudicial that the plaintiff's expert witnesses were not paid for their services because she was indigent, believing that the lack of payment placed in doubt their credibility and claiming that the paid tobacco expert witnesses had more motive to testify independently because they had been paid, a perverse and novel line of reasoning. The McTear case contrasts unfavourably with the recent decision in United States v. Philip Morris, a United States decision that found the tobacco industry defendants to be racketeers, based both on the weight of a huge amount of internal tobacco industry documents showing that the tobacco industry knew their products were addictive and were made that way purposely to increase sales, and on the testimony of expert witnesses who, like those who testified in McTear, have made the advancement of the public health their life's work and are not "hired guns". The McTear case's reasoning seems outdated and reminiscent of early litigation in the United States. Hopefully, it will not take courts outside of the United States 40 more years to acknowledge the current scientific knowledge about smoking and health.
Collapse
Affiliation(s)
- L Friedman
- Public Health Advocacy Institute, Northeastern University School of Law, Boston, Massachusetts 02115, USA.
| | | |
Collapse
|
46
|
|
47
|
Friedman L, Naeim A, Pasta D, Elkin E, Viswanathan H, Glaspy J. 1139 POSTER Treatment patterns and patient characteristics associated with treatment for chemotherapy-induced anaemia in community-based oncology practices in the U.S. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70658-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Friedman L, Naeim A, Pasta DJ, Elkin EP, Viswanathan H, Kallich J, Glaspy J. Adherence to anemia treatment guidelines in U.S. community oncology practices. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.19525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
19525 Background: Adherence to anemia guidelines may improve patient outcomes including health-related quality of life. This analysis presents baseline guideline adherence among community-based oncology practices prior to an educational intervention targeted to health care providers to improve adherence to anemia guidelines. Methods: Medical records of a sequential sample of adult cancer patients receiving chemotherapy from 47 participating sites during the year prior to site randomization to an educational intervention were abstracted. Each chart was analyzed to determine (1) whether or not the patient met the criteria for anemia treatment with an erythropoiesis- stimulating agent (ESA) or a blood transfusion, and (2) whether the patient received anemia treatment. A complex algorithm was developed to evaluate whether treatment adhered to guideline recommendations. Results: This baseline analysis included 2463 patient charts. Most patients were female (66%); with a mean duration of cancer of 14.5 months and a mean age of 61.8 years. According to guidelines, 523 patients (21%) met the criteria for anemia treatment and of these, 286 (55%) received an ESA or transfusion. In 1103 patients (45%), guidelines suggested that anemia treatment may be inappropriate. However, 216 (20%) of the 1103 patients for whom guidelines recommend against treatment received an ESA or transfusion. For 837 patients (34%), the guidelines did not provide a definitive recommendation and 242 (29%) of such patients received an ESA or transfusion. Conclusions: Baseline assessment found that many patients did not receive treatment consistent with anemia guidelines. This study will evaluate whether a year long educational intervention can improve clinician adherence to guideline recommendations, thereby improving patient outcomes. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Friedman
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - A. Naeim
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - D. J. Pasta
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - E. P. Elkin
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - H. Viswanathan
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - J. Kallich
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| | - J. Glaspy
- McKesson Specialty Oncology Services, San Rafael, CA; UCLA, Los Angeles, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA
| |
Collapse
|
49
|
Naeim A, Friedman L, Pasta DJ, Elkin EP, Malin J, Viswanathan H, Ozer H. Prophylaxis of chemotherapy-induced neutropenia: Patterns of care in U.S. community oncology practices. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9123 Background: Adherence to neutropenia guidelines may improve patient outcomes and decrease costs associated with febrile neutropenia (FN). This analysis presents baseline data on patterns of colony-stimulating factor (CSF) use among community-based oncology practices prior to an educational intervention targeted to health care providers to improve adherence to CSF guidelines from the National Oncology Alliance (NOA). Methods: Medical records were identified from 47 participating sites. Abstractors collected data from a sequential sample of adult cancer patients receiving chemotherapy during the year prior to site randomization to an educational intervention (June and August 2006). A complex algorithm was developed to identify patients for whom the NOA guidelines recommend primary prophylaxis with a CSF including (1) patients receiving a chemotherapy regimen with a >20% expected risk of FN and (2) patients receiving chemotherapy with a 10–20% risk of FN and who have one of the following risk factors present: diminished performance status or non-Hodgkin's lymphoma with low serum albumin or high serum LDH or spread to bone marrow. Results: 2594 patients were evaluated for this analysis. Most were female (66%) and the mean age was 61.7 years (± 13.1). During this period (2005–06), 423 (16%) patients received chemotherapy regimens with an FN risk >20% and 143 (6%) received chemotherapy regimens with an FN risk of 10–20% and had a risk factor. Of patients receiving chemotherapy with a >20% risk of FN, 176 (42%) received CSF primary prophylaxis. Of patients receiving chemotherapy with a 10–20% risk FN with a risk factor present, 40 (28%) received CSF primary prophylaxis. Conclusions: Many patients for whom guidelines recommend treatment did not receive CSF primary prophylaxis. After the year-long educational intervention, we will re-evaluate CSF patterns of care and assess whether adherence to guidelines improved patient outcomes. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Naeim
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - L. Friedman
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - D. J. Pasta
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - E. P. Elkin
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - J. Malin
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - H. Viswanathan
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| | - H. Ozer
- UCLA, Los Angeles, CA; McKesson Specialty Oncology Services, San Rafael, CA; Ovation Research Group, San Francisco, CA; Amgen, Thousand Oaks, CA; University of Oklahoma, Oklahoma City, OK
| |
Collapse
|
50
|
Affiliation(s)
- L. Friedman
- a Department of Theoretical Physics , University of St. Andrews , St. Andrews KY16 9SS, Fife , Scotland
| | - M. Pollak
- b Department of Physics , University of California , Riverside , California , 92502 , U.S.A
| |
Collapse
|